For the first time in twenty years, Australians living with rare IDH-mutant brain tumours have a new therapeutic option — not merely a new drug, but access to one, as vorasidenib joins the Pharmaceutical Benefits Scheme this week. The listing transforms a $28,000 monthly cost into $25, placing within reach a treatment that can slow or halt the progression of cancers that quietly dismantle the lives of people in the prime of their working and family years. In a disease where time is the most precious currency, this decision by Australia's health authorities is an act of collective care — a reco
First brain cancer treatment in 20 years added to PBS, slashing costs for patients
Approximately 3,230 Australians live with these incurable brain tumours, experiencing seizures, cognitive changes, physical disability, and loss of independence over many years.
A treatment that might buy them years, and the ability to afford it
Mark
Why does it matter that this is the first new treatment in 20 years?
Mimi
Because for two decades, doctors have been working with the same limited tools—surgery, radiation, chemotherapy. None of them stop the disease. They just slow it down. A new mechanism, a new way of attacking the cancer at the genetic level, changes what's possible.
Mark
And the PBS listing—that's about money, obviously, but is it about something else too?
Mimi
It's about who gets to live. At $28,000 a month, this drug was a luxury item. Most Australians can't access it, no matter how much their doctor believes it could help. The PBS listing says: this matters enough that we all share the cost. It's a statement of value.
Mark
The source mentions that patients are typically diagnosed young—20s to 40s. Does that change how we should think about this?
Mimi
Completely. These are people in the middle of their lives. They're building careers, raising children, making plans. The disease steals those things gradually. A treatment that slows it down doesn't cure it, but it might give someone five more years with their kids, or ten more years working. That's not nothing.
Mark
What about the side effects? Liver damage, fatigue—those sound serious.
Mimi
They are. But they're manageable with monitoring, and they're a trade-off patients are willing to make. The alternative is watching the disease progress without any medical intervention beyond surgery or radiation. Most people will choose monitored side effects over that.
Mark
The brain tumour collaborative spokesperson said access to medication is only part of the answer. What's the rest?
Mimi
The disease doesn't just affect the patient's body. It affects their mind, their independence, their family's ability to cope. You need psychologists, social workers, practical support services. A drug that slows the cancer is only useful if the person taking it has the support to actually live while they're taking it.
O Pulso
- Roughly 3,230 Australians carry a diagnosis that steals cognition, movement, and independence across years — and until now, no new treatment had emerged in two decades.
- A drug capable of blocking the genetic mutations driving these tumours existed, but its $28,000 monthly price tag made it functionally inaccessible to most patients.
- The PBS listing slashes that cost to $25 — or $7.70 on concession — opening the treatment to the approximately 135 Australians newly diagnosed each year.
- Clinicians welcome the expanded toolkit, but caution that vorasidenib requires liver function monitoring and sits within a broader need for multidisciplinary and psychosocial care.
- For patients diagnosed in their twenties to mid-forties, the listing offers something rare in this disease: the possibility of buying years without the cost of financial ruin.
For the first time in twenty years, Australians living with rare IDH-mutant brain tumours have a new therapeutic option — not merely a new drug, but access to one, as vorasidenib joins the Pharmaceutical Benefits Scheme this week. The listing transforms a $28,000 monthly cost into $25, placing within reach a treatment that can slow or halt the progression of cancers that quietly dismantle the lives of people in the prime of their working and family years. In a disease where time is the most precious currency, this decision by Australia's health authorities is an act of collective care — a recognition that medical progress means little if only the wealthy can afford to benefit from it.
For the first time in two decades, patients with a rare and incurable brain cancer have a new treatment option — and, crucially, the means to afford it. Vorasidenib, a drug that targets the IDH1 and IDH2 gene mutations driving certain brain tumours, was this week added to the Pharmaceutical Benefits Scheme, reducing monthly costs from more than $28,000 to a maximum of $25, or $7.70 with a concession card.
The drug treats IDH-mutant astrocytoma and oligodendroglioma — the most common malignant primary brain cancers in adults under 50. Around 3,230 Australians live with these conditions, most diagnosed between their twenties and mid-forties. The disease moves slowly but without mercy: seizures emerge, thinking clouds, physical capacity diminishes. Previous options — surgery, radiation, chemotherapy, watchful waiting — could only delay the inevitable. Vorasidenib offers something different, blocking the mutated proteins that cause tumours to form and spread, slowing or halting progression rather than simply managing its consequences.
Health Minister Mark Butler described the listing as a milestone, offering patients what he called "precious time." Associate Professor Jim Whittle of Peter MacCallum Cancer Centre noted that treatment decisions in this disease always involve balancing disease control against preserving neurological function and quality of life — and that vorasidenib gives doctors and patients more room to navigate that balance.
The Australian Brain Tumour Collaborative welcomed the news while noting that medication access is only one part of what patients need. Coordinated multidisciplinary care, psychological support, and practical guidance remain essential alongside the drug itself, which carries side effects including liver enzyme elevation, fatigue, and nausea requiring ongoing monitoring. For the roughly 135 Australians diagnosed each year, the PBS listing means a treatment that might extend their years is now something they can actually afford.
For the first time in two decades, patients living with a rare and incurable brain cancer have a new weapon against the disease. This week, vorasidenib—a drug that blocks the abnormal proteins driving certain brain tumours—was added to the Pharmaceutical Benefits Scheme, transforming what had been a prohibitively expensive treatment into one that costs patients a maximum of $25 per prescription, or $7.70 with a concession card.
The drug targets IDH-mutant astrocytoma and oligodendroglioma, brain tumours that, while uncommon, represent the most frequent malignant primary brain cancers in adults under 50. An estimated 3,230 Australians currently live with these conditions. Most are diagnosed between their twenties and mid-forties, at an age when they might otherwise expect decades of working life and family building ahead. The disease unfolds slowly but relentlessly: seizures begin, thinking becomes foggy, physical abilities fade, independence slips away. Until now, doctors could only offer surgery, close monitoring, radiation, or chemotherapy—all aimed at slowing the inevitable rather than stopping it.
Vorasidenib works by targeting the genetic mutations—specifically in the IDH1 or IDH2 genes—that cause these cancers to form and spread. By blocking the mutated proteins these genes produce, the drug can slow or halt disease progression. Without the PBS listing, a month's supply would cost patients upward of $28,000. That price tag placed the treatment beyond reach for most Australians. The subsidy changes that calculus entirely, making it accessible to the roughly 135 people diagnosed with this cancer each year.
Health Minister Mark Butler called the listing a milestone for a disease that has long lacked options. "This is the first new treatment in 20 years being listed for a rare brain cancer, which can slow disease progression," he said, framing the approval as offering patients "precious time." Associate Professor Jim Whittle, a medical oncologist at Peter MacCallum Cancer Centre, emphasized that managing these tumours requires balancing disease control against preserving the neurological function and quality of life that patients still have. Adding vorasidenib to the treatment toolkit gives doctors and patients more choices in that difficult negotiation.
Craig Cardinal, speaking for the Australian Brain Tumour Collaborative, welcomed the listing but sounded a note of caution. Access to medication, he noted, is only part of the answer. Patients and their families need coordinated care across multiple disciplines, psychological support, and practical help navigating the long journey ahead. The drug itself carries side effects—elevated liver enzymes, fatigue, headache, diarrhoea, nausea, muscle aches, and stiffness—that require monitoring, particularly liver function tests before and during treatment.
Mélanie Chamaux, general manager of Servier Australia and New Zealand, the company that manufactures Voranigo, described the PBS listing as recognition of therapeutic progress and the difference innovative medicines can make. For patients and families facing this disease, the listing represents something more immediate: a treatment that might buy them years, and the ability to afford it without financial ruin.
Citações Notáveis
This is the first new treatment in 20 years being listed for a rare brain cancer, which can slow disease progression. Listing Voranigo will benefit around 135 Australians diagnosed with this rare, incurable brain cancer each year, offering these patients a treatment option that can give them precious time.— Health Minister Mark Butler
Access to treatment is only one part of the journey. People living with brain cancer and their families also need coordinated multidisciplinary care, psychosocial support and practical services throughout every stage of their diagnosis.— Craig Cardinal, Australian Brain Tumour Collaborative
Quer a matéria completa?
Leia o original em Nine.com.au ↗
Health & Medicine